ILMN

Illumina, Inc.

Next est. report 2026-07-30 · AMC

Cycle Long '24: Health & Life SciencesGenomics '25: Sequencing HardwareMedTech Long '25: Diagnostic Platforms MedTech Long '26: Diagnostics & Early Detection MedTech Long '26: Life Science Tools & Bioprocessing

Loading…

Overview

Illumina, Inc. (ILMN) provides genetic and genomic analysis tools, including sequencing instruments like NovaSeq X and consumables, for research and clinical us

Illumina, Inc. (ILMN) provides genetic and genomic analysis tools, including sequencing instruments like NovaSeq X and consumables, for research and clinical use. Its offerings support life sciences, cancer diagnostics, and reproductive health. Clinical applications drive over 65% of sequencing consumables revenue, with strong NovaSeq X placements. The company serves genomic research facilities, medical centers, and biotech firms globally.

What They Do (Plain English & Analogies): Illumina is like a high-tech detective agency for your genes. They make the specialized tools and chemicals that scientists and doctors use to "read" the entire genetic instruction book (DNA) of a person, animal, or plant. This helps them understand what makes us unique, what causes diseases like cancer, how to develop new medicines, or even how to improve crops. They provide the "microscopes" (sequencing machines) and the "slides and stains" (reagents and arrays) to uncover these genetic secrets, and they also offer services to help analyze the massive amounts of data generated.
Very Brief History: Illumina, Inc. was founded in April 1998 and is headquartered in San Diego, California. Since its inception, the company has focused on developing and commercializing integrated systems for genetic analysis, evolving into a global leader in sequencing and array technologies.
"Street Stereotype": Illumina is generally perceived as the dominant incumbent in the next-generation sequencing (NGS) hardware and consumables market. It's seen as the foundational technology provider for much of the global genomics research and clinical testing infrastructure, particularly for liquid biopsy and multiomics. While facing increasing competition, especially in lower-cost sequencing, its NovaSeq X platform is viewed as a key driver for future growth and maintaining its market leadership.
Subsidiaries On Linked In*: Illumina GmbH — German subsidiary mentioned in a patent case
Customer Sectors & Example Clients: Illumina's customers span a wide range of sectors including: genomic research facilities, universities and academic institutions, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, businesses focused on consumer genomics, and agriculture (agrigenomics). Example clients (educated guesses based on industry leaders and common users of NGS technology): Broad Institute, Mayo Clinic, Quest Diagnostics, LabCorp, Amgen, 23andMe.
New Customers / Segments They'Re Targeting: Illumina is actively targeting new applications and segments to drive growth. These include expanding sequencing-based diagnostics and more sequencing-intensive applications in clinical markets, particularly for rare diseases, comprehensive genomic profiling, and whole genome sequencing. They are also investing in proteomics (following the SomaLogic acquisition), single-cell technologies, and spatial transcriptomics, with a launch planned for later this year. Furthermore, with BioInsight and the Billion Cell Atlas program, they are targeting partners interested in leveraging large-scale genomic data to support AI-driven models for drug discovery.
Supply Chain And Sourcing Geographies: The transcript indicates that Illumina experienced "supply constrained" NovaSeq X units in Q1 2026 and is investing to scale supply. The company also noted "inflationary pressures related to freight costs and higher cost of electronic components." While specific sourcing geographies are not detailed, the mention of electronic components suggests reliance on a global electronics supply chain, likely including East Asia. Illumina's global operations, including manufacturing and supply chain, are managed by its Chief of Global Operations. Without more explicit information in the transcript or high-confidence public sources, specific country/region details for component sourcing remain uncertain.
Sales Geographies And Expansion Plans: Illumina sells its products directly to clients across North America, Europe, Latin America, and the Asia-Pacific. They also utilize life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. The company's reporting segments include "Rest of World organic growth" and considers the impact from its "Greater China region," confirming active sales in these areas. Management did not explicitly disclose plans to expand sales into entirely new geographies, but rather emphasized expanding market penetration within existing regions, especially in clinical applications.
How Key Themes May Help/Hurt: The **MedTech Long '26: Diagnostics & Early Detection** theme is highly relevant to Illumina. The theme's bullish drivers, such as accelerating technological advancements in genomics and multiomics (Bull1), directly benefit Illumina as a leader in these areas. The increasing global prevalence of chronic diseases, especially cancer (Bull2), fuels demand for advanced diagnostic solutions, which heavily rely on Illumina's sequencing technology. Favorable regulatory developments for multi-cancer early detection (MCED) tests (Bull3) could unlock substantial market opportunities, increasing demand for Illumina's platforms and consumables. The company's strong clinical consumables growth (20% ex-China) and NovaSeq X placements in clinical markets directly align with these tailwinds. Conversely, potential headwinds from this theme include persistent reimbursement pressures and evolving payer policies (Bear1), which could impact the profitability and market uptake of novel tests running on Illumina's platforms, indirectly affecting consumables sales. Significant regulatory hurdles (Bear2) for new diagnostic tests could delay their commercialization and adoption, while intensifying competition (Bear3) in the diagnostics and early detection space could lead to pricing pressures that might eventually extend to Illumina's offerings.

3 Main Long-Term Bull Details

Dominance in Clinical Genomics and NovaSeq X Adoption: Illumina is experiencing sustained and robust growth in clinical markets, with clinical consumables growing 20% ex-China for two consecutive quarters. The NovaSeq X platform is seeing strong demand and placements, especially in clinical settings, and is becoming increasingly embedded in clinical workflows for applications like comprehensive genomic profiling and whole genome sequencing. This expanding clinical installed base is expected to drive long-term consumables revenue.
Continuous Innovation and Expanding Platform Value: Illumina is committed to continuous innovation on its NovaSeq X platform, including new flow cells (14B, 35B), improved data quality (Q70), and enhanced workflow efficiency. The company is also expanding into new areas like spatial transcriptomics (launching later this year) and proteomics (through the SomaLogic acquisition), and leveraging data and AI with initiatives like BioInsight and the Billion Cell Atlas. These innovations increase the value and utility of Illumina's platforms, ensuring their relevance and driving future demand.
Strong Financial Trajectory and Operational Discipline: Despite a dynamic macro environment, Illumina has demonstrated disciplined execution, leading to Q1 2026 revenue, margin, and EPS all above guidance. The company is raising its full-year 2026 guidance and remains on track for its 2027 targets of high single-digit revenue growth, continued margin expansion, and double-digit to teens EPS growth. This financial performance, coupled with strong operational discipline in managing costs, provides confidence in long-term sustainable growth.

3 Main Long-Term Bear Details

Cautious Research and Academic Market Demand: Demand in research and academic markets remains cautious due to funding uncertainty, leading to a decline in sequencing consumables in this segment. While some improvement is anticipated, a prolonged cautious environment could hinder overall revenue growth, as these markets serve as important entry points for new technologies.
Competitive Pressures and Pricing Elasticity: While Illumina maintains a dominant position, the competitive landscape is evolving with new entrants and technologies. The discussion around "elasticity" and aggressive pricing for high-volume customers, especially with the upcoming 35B flow cell, suggests potential for pricing pressures, even if it drives volume. The presence of competitors like Element Biosciences and 10x Genomics, and the anticipation of others, could challenge Illumina's market share and margins.
Supply Chain Constraints and Inflationary Pressures: Illumina experienced supply constraints for NovaSeq X units in Q1 2026 and is facing inflationary pressures related to freight costs and electronic components. While the company is taking mitigating actions, persistent supply chain issues or unmanaged cost increases could impact instrument placements, production, and ultimately, profitability and margin expansion targets.

Competitors And Differentiation: Illumina's competitors include other sequencing platform providers such as PacBio (long-read sequencing), Element Biosciences, Oxford Nanopore Technologies, MGI (China's challenger), Thermo Fisher Scientific (Ion Torrent NGS systems), and Roche (AXELIOS 1 / SBX sequencing technology). In spatial biology, 10x Genomics is a competitor. Illumina differentiates itself through: its dominant market position and large installed base of NovaSeq X instruments, which drives consumables growth; continuous innovation on the NovaSeq X platform, including new flow cells and improved data quality; a focus on end-to-end workflow solutions encompassing instruments, library prep (TruPath), data analysis (BioInsight, DRAGEN, Illumina Connected Analytics), and spatial offerings; and an emphasis on the quality and reliability of its technology, particularly with strong momentum and investment in clinical applications.
Recent Performance & What The Market'S Focused On: Illumina had a strong start to 2026, with Q1 revenue of $1.09 billion, up 4.8% year-over-year, and non-GAAP diluted EPS of $1.15, up 19% year-over-year, both above guidance. This performance was driven by better-than-expected instrument sales, with over 80 NovaSeq X placements (exceeding the targeted 50-60 per quarter), and strong clinical consumable sales (up 20% ex-China). The company raised its full-year 2026 revenue outlook to $4.52 billion to $4.62 billion and its non-GAAP diluted EPS outlook to $5.15 to $5.30. The market is focused on: NovaSeq X placements and utilization, particularly in clinical markets, and the company's ability to scale supply; the sustainability of robust clinical market momentum; the timing and extent of a rebound in research and academic spending; the company's ability to expand operating margins despite inflationary pressures; the impact of new competitive offerings; and the successful launch and adoption of new product innovations like spatial transcriptomics and TruPath.

Revenue Segments And Estimated Mix: Sequencing Consumables — Mix: ~66.6%; Source: Q1 2026 transcript; Trend: Up 4% YoY; Clinical sequencing consumables up 20% ex-China; Research and applied declined 12% ex-China. Clinical made up >65% of sequencing consumables revenue.
Sequencing Instruments — Mix: ~10.8%; Source: Q1 2026 transcript; Trend: Up 9% YoY; Driven by increased NovaSeq X sales.
Sequencing Service and Other — Mix: ~13.9%; Source: Q1 2026 transcript; Trend: Up 7% YoY.
Microarrays — Mix: ~8.7%; Source: Q1 2026 transcript (calculated residual); Trend: Down 20% on a Rest of World organic basis; includes SomaLogic revenue.
Product Brands: NovaSeq X Series
NovaSeq 6000 System
MiSeq i100 Series
MiSeq System
NextSeq 1000 & 2000 Systems
NextSeq 550 System
iSeq 100 System
TruPath
BioInsight
Billion Cell Atlas
5-Base Solution
DRAGEN Secondary Analysis
Illumina Connected Analytics
Infinium (microarray technology)
iScan System
fireflyGO
Trusight Oncology
Illumina DNA Prep
Pillar oncoReveal
TruSight Panels
AmpliSeq for Illumina
XLEAP-SBS chemistry
StrataMap Spatial solution
SOMAmer proteomics

Bull / Bear Details

Illumina maintains a bullish outlook driven by exceptional clinical market momentum, with sequencing consumables growing 20% ex-China, and robust NovaSeq X plac

Thesis

Illumina maintains a bullish outlook driven by exceptional clinical market momentum, with sequencing consumables growing 20% ex-China, and robust NovaSeq X placements exceeding expectations. Strategic innovation, including TruPath and spatial transcriptomics, enhances platform value and future growth. Despite ongoing caution in research markets and near-term inflationary pressures, the company's strong Q1 performance and raised 2026 guidance reinforce its path toward sustainable high single-digit revenue and double-digit EPS growth by 2027. (Updated: 2026-07-23)

Bull case

Illumina is experiencing robust demand in clinical markets, with sequencing consumables (ex-China) growing 20% year-over-year for two consecutive quarters, now comprising over 65% of consumables revenue. This sustained growth is fueled by expanding sequencing-based diagnostics and more data-intensive applications, indicating a long runway for continued clinical business expansion and NovaSeq X utilization.
The company's innovation pipeline, including the successful launch of TruPath for simplified whole-genome sequencing in rare disease and the upcoming spatial transcriptomics offering, is expanding platform utility. The NovaSeq X roadmap, featuring new 14B and 35B flow cells, further enhances throughput and efficiency, driving strong instrument placements and future consumables pull-through.
Illumina delivered a strong Q1 2026, exceeding revenue, margin, and EPS guidance, leading to a raised full-year 2026 outlook. Over 80 NovaSeq X placements in Q1, despite supply constraints, demonstrate robust demand. The company remains on track for its 2027 targets of high single-digit revenue growth and double-digit to teens EPS growth, reflecting disciplined execution and operational leverage.

Bear case

Demand in research and academic markets remains cautious due to funding uncertainty, with sequencing consumables (ex-China) declining 12% in Q1. While NIH funding is expected to improve, the translation into actual spending on tools and consumables is slow, posing a continued headwind to a significant portion of Illumina's business.
Near-term operating margins face pressure from a higher instrument revenue mix, inflationary costs (freight, electronic components), and the full integration of SomaLogic. Although mitigating actions are underway, these factors are expected to impact Q2 margins, with improvements anticipated only in the latter half of the year, potentially affecting short-term profitability.
The competitive landscape continues to intensify, with discussions around aggressive pricing (e.g., $150 per genome) from new entrants. While Illumina expresses confidence, the need to offer volume discounts on NovaSeq X placements and the cautious stance on 35B flow cell pricing suggest potential future pricing pressures and increased competition for market share.

Bull / Bear Case

Bear Case: Demand in research and academic markets remains cautious due to funding uncertainty, with sequencing consumables (ex-China) declining 12% in Q1 2026. While NIH funding is expected to improve, the translation into actual spending on tools and consumables is slow, posing a continued headwind to a significant portion of Illumina's business. Near-term operating margins face pressure from a higher instrument revenue mix, inflationary costs (freight, electronic components), and the full integration of SomaLogic, with improvements anticipated only in the latter half of the year. The competitive landscape continues to intensify, with discussions around aggressive pricing (e.g., $150 per genome) from new entrants. The need to offer volume discounts on NovaSeq X placements and the cautious stance on 35B flow cell pricing suggest potential future pricing pressures and increased competition for market share.
Bull Case: Illumina is demonstrating robust demand in clinical markets, with sequencing consumables (ex-China) growing 20% year-over-year for two consecutive quarters, now comprising over 65% of consumables revenue. This growth is driven by expanding diagnostics and data-intensive applications, indicating a long runway for clinical business expansion and NovaSeq X utilization. The company's innovation pipeline, including the successful launch of TruPath and the upcoming spatial transcriptomics offering, is expanding platform utility. The NovaSeq X roadmap, featuring new 14B and 35B flow cells, further enhances throughput and efficiency, driving strong instrument placements (over 80 in Q1 2026 despite supply constraints) and future consumables pull-through. Illumina delivered a strong Q1 2026, exceeding revenue, margin, and EPS guidance, leading to a raised full-year 2026 outlook and reinforcing its path toward sustainable high single-digit revenue and double-digit to teens EPS growth by 2027.
More Compelling & Why: Bear. Illumina's current P/E ratio (TTM) of approximately 33.46-34.70 is high, and the stock is considered 'Significantly Overvalued' by some analyses. The strongest argument for the bear case is this stretched valuation, especially given the persistent cautiousness in the research market and ongoing competitive and inflationary pressures impacting margins. A consensus analyst rating of 'Hold' with price targets implying downside further supports this view. My view would flip to bullish if the company demonstrates sustained, accelerated revenue growth beyond current guidance, particularly in the research segment, coupled with clear evidence of margin expansion and a significant reduction in competitive pricing pressure, or a substantial correction in the stock price to align with intrinsic value assessments.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Successful launch of the Spatial Transcriptomics offering	This new product expands Illumina's portfolio into the high-growth spatial biology market, addressing challenging sample types and potentially driving new instrument and consumables sales, diversifying revenue streams.	Official launch announcement and initial customer feedback/adoption rates for the spatial transcriptomics offering. Expected launch is 'later this year' (2026).	Bullish: Official launch of the spatial transcriptomics offering in H2 2026 with positive initial customer feedback and strong early order indications.	Illumina's company press releases, investor presentations, and future earnings calls (Q2 2026, Q3 2026 earnings calls).	Google Trends: 'Illumina spatial transcriptomics' search volume; scientific conference presentations (e.g., AGBT, AACR) for new data.	Thinknum: Job postings for 'spatial biology specialist' at Illumina; Similarweb: Web traffic to Illumina's spatial biology product pages post-launch.
Achievement of NovaSeq X clinical volume transition target and sustained high pull-through	The transition of clinical volumes to NovaSeq X is crucial for realizing the full economic benefits of the platform, including higher throughput and efficiency, and ensuring long-term consumables revenue growth.	Percentage of clinical volume transitioned to NovaSeq X. Management expects 80-85% of clinical volumes to be on X by the end of 2026. Also, monitor NovaSeq X pull-through (currently above $1.3 million).	Bullish: Clinical volume on NovaSeq X reaches or exceeds 80% by Q4 2026, demonstrating successful platform transition and sustained high utilization.	Illumina's quarterly earnings calls and investor presentations (Q2 2026, Q3 2026, Q4 2026 earnings calls).	Industry reports on sequencing platform adoption trends.	Earnest Analytics: Consumables sales data for NovaSeq X vs. older platforms.
NovaSeq X Instrument Placements exceeding guidance and supply constraints	High NovaSeq X placements directly indicate strong market adoption of Illumina's flagship platform, which is crucial for driving future high-margin sequencing consumables revenue approximately six months post-installation.	Number of NovaSeq X units placed in Q2 2026 and subsequent quarters. Management expects Q2 placements to be similar to Q1 (80+ units) and a robust pipeline for H2 2026.	Bullish: Q2 2026 NovaSeq X placements at or above 80 units, indicating sustained strong demand and successful scaling of supply.	Illumina's quarterly earnings calls and press releases (Q2 2026 earnings call typically late July/early August 2026). SEC filings (10-Q).	Industry news reports on sequencing instrument sales; competitor earnings calls for market commentary.	Earnest Analytics: Diagnostic device sales data for high-throughput sequencers.
Sustained double-digit growth in Clinical Sequencing Consumables Revenue (ex-China)	Clinical applications are the primary growth engine for Illumina, representing over 65% of sequencing consumables revenue. Continued strong growth here validates the expansion of sequencing-based diagnostics and adoption of intensive applications.	Rest of World organic clinical sequencing consumables revenue growth rate in Q2 2026 and beyond. Management expects mid-teens growth for the full year and no signs of deceleration.	Bullish: Clinical sequencing consumables (ex-China) growth remains at or above mid-teens year-over-year, confirming continued robust adoption.	Illumina's quarterly earnings calls and press releases (Q2 2026 earnings call typically late July/early August 2026). SEC filings (10-Q).	NIH funding for clinical genomics research; public health reports on diagnostic test adoption.	Earnest Analytics: Diagnostic test volume & sales data for sequencing-based diagnostics.
Improvement in Research & Academic Market Demand	While currently a headwind, a recovery in this market, supported by easing funding uncertainty and with most volumes already on NovaSeq X, represents a significant upside opportunity without previous pricing pressures.	Year-over-year growth rate for Research and Applied sequencing consumables (ex-China). Management noted this as a potential upside to current guidance.	Bullish: Research and Applied sequencing consumables (ex-China) growth turns positive year-over-year, indicating a recovery in funding and spending.	Illumina's quarterly earnings calls and press releases (Q2 2026 earnings call typically late July/early August 2026). NIH funding announcements.	NIH Reporter: New grant awards for genomics research; Google Trends: 'genomics research funding' or 'NIH grants'.	EvaluatePharma: Biotech R&D funding trends; Thinknum: Academic institution job postings for genomics researchers.

Key Reported Metrics, Reratings Triggers & Results3 rows

This segment is a primary growth driver, making up over 65% of consumables revenue, reflecting increasing adoption of sequencing-based diagnostics and more data

Key reported metrics			Rerating thresholds
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date
Clinical Sequencing Consumables Revenue (ex China)	20%	This segment is a primary growth driver, making up over 65% of consumables revenue, reflecting increasing adoption of sequencing-based diagnostics and more data-intensive applications. Continued strong growth here validates Illumina's strategy in high-value clinical markets.	For Illumina (ILMN) to rerate higher, the Clinical Sequencing Consumables Revenue (ex China) metric needs to maintain or exceed its current 20% year-over-year growth rate in Q2 2026. This would align with recent analyst upgrades and their bullish sentiment, which anticipates another quarter near 20% growth to justify higher price targets.	This metric is a primary growth driver, reflecting increasing adoption of sequencing-based diagnostics and robust NovaSeq X utilization. Sustained growth at or above 20% validates Illumina's strategy in high-value clinical markets, justifying a premium valuation and confirming the bullish investment thesis.	2026-07-30
Non-GAAP Diluted EPS	19%	As a key bottom-line metric, Non-GAAP Diluted EPS reflects Illumina's overall profitability and operational efficiency. Strong EPS growth indicates effective cost management and leverage from revenue growth, directly impacting shareholder value.	For the stock to rerate higher, Illumina's Non-GAAP Diluted EPS for Q2 2026 needs to exceed its guidance range of $1.20 to $1.25, ideally hitting $1.28 or higher, and the company should either raise or reaffirm the high end of its full-year 2026 guidance of $5.15 to $5.30.	Exceeding EPS expectations would confirm robust clinical market momentum and NovaSeq X adoption, demonstrating strong operational execution and mitigating concerns about research market softness and competitive pressures. This performance would justify a higher valuation multiple and reinforce investor confidence in Illumina's path to sustainable double-digit EPS growth.	2026-07-30
NovaSeq X Placements	33.3%	High NovaSeq X placements indicate strong customer adoption of Illumina's flagship platform, which is crucial for driving future, high-margin consumables revenue. It signals market leadership and expansion into clinical workflows.	NovaSeq X Placements (representing the percentage of clinical volume transitioned to NovaSeq X) needs to reach 45-50% or higher in Q2 2026, demonstrating significant acceleration towards the 80-85% year-end target. Additionally, NovaSeq X instrument placements should exceed 80 units in Q2.	Hitting this threshold demonstrates accelerated adoption of Illumina's flagship NovaSeq X platform, crucial for driving future high-margin consumables revenue and confirming market leadership. It signals successful scaling of supply and strong progress towards the 80-85% clinical volume transition target by year-end, validating the company's growth strategy and competitive position.	2026-07-30

Key Questions

Given the strong NovaSeq X placements and supply constraints in Q1, can Illumina effectively scale production and maintain robust placement momentum in Q2, whil

Given the strong NovaSeq X placements and supply constraints in Q1, can Illumina effectively scale production and maintain robust placement momentum in Q2, while also demonstrating the anticipated acceleration in consumables pull-through from the expanding installed base?

Question 2: Will the cautiousness in the research and academic markets persist, or will the anticipated pick-up in NIH funding translate into a meaningful recovery in sequencing consumables demand, thereby providing an upside to Illumina's current conservative guidance for this segment?
Question 3: Can Illumina successfully execute its mitigating actions to offset inflationary pressures and manage potential competitive pricing dynamics, thereby achieving the projected operating margin expansion in the second half of 2026, particularly given the higher instrument mix and full quarter impact of SomaLogic in Q2?

Earnings Transcript SummaryTable

2026-04-30 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
1. Disciplined Commercial Execution and Clinical Market Momentum: Management highlighted strong Q1 performance, exceeding guidance, driven by disciplined execution and robust demand in clinical markets. Clinical made up over 65% of sequencing consumables revenue, reflecting continued adoption of sequencing-based diagnostics and more sequencing-intensive applications, which is fueling NovaSeq X placements in clinical settings. 2. Product Innovation and Roadmap Updates: Jacob Thaysen emphasized R&D efforts, including the launch of TruPath for whole genome sequencing, significant customer interest in their spatial transcriptomics offering (on track for launch later this year), and the 18-month roadmap for NovaSeq X, which includes new flow cells (14B and 35B) and improved data quality (Q70). This demonstrates a commitment to expanding the value and capabilities of their platforms. 3. Progress Against Long-Term Strategy and Targets (including NovaSeq X Expansion): Management reiterated confidence in their strategy, noting that the NovaSeq X is central to scaling and expanding customer applications, thereby driving consumables growth. They are raising 2026 guidance and remain on track for their 2027 targets of high single-digit revenue growth, continued margin expansion, and double-digit to teens EPS growth. They also highlighted the successful SomaLogic acquisition and investments in BioInsight and the Billion Cell Atlas.	The overall takeaway of the call was highly positive and confident. Illumina had a strong start to 2026, exceeding Q1 guidance for revenue, margin, and EPS, primarily driven by robust demand in clinical markets and strong NovaSeq X placements. Management expressed confidence in their long-term strategy, emphasizing continuous innovation, NovaSeq X expansion, and disciplined operational execution to drive sustainable growth and margin expansion. While acknowledging ongoing cautiousness in research markets and some near-term inflationary pressures, they conveyed optimism about their ability to mitigate these challenges and achieve their long-range targets, leading to a raised full-year 2026 guidance.	For Q4 2025, total revenue was up 5% year-over-year. Sequencing consumables revenue increased 8% year-over-year (11% excluding China). Clinical sequencing consumables, excluding China, grew 20% year-over-year. Sequencing instruments revenue was flat year-over-year (0%). Sequencing service and other revenue was up 4% year-over-year. Specific year-over-year growth percentages for 'Research and applied sequencing consumables (ex China)' and 'Microarrays business' were not explicitly provided in the Q4 2025 search results; however, research and academic demand was noted as subdued in Q4 2025.	1. Full-year organic revenue guidance vs. Q1 outperformance: Analysts questioned why the full-year organic revenue guidance wasn't raised more significantly despite the strong Q1 beat, particularly in instruments and clinical. Management (Jacob and Ankur) responded that raising both top and bottom line guidance after only one quarter signals confidence, and the $20 million revenue guidance increase moves them towards the higher end of the previously stated range, representing approximately a 0.5 percentage point increase. 2. NovaSeq X instrument demand, mix, and pricing transition: Analysts pressed on the impressive NovaSeq X placements (over 80 in Q1), asking about the mix between clinical and research, the impact of the NovaSeq 6000 to NovaSeq X pricing transition on consumables, and the outlook for future placements. Management stated that over 60% of placements were clinical and largely incremental, not just conversions. They noted that most research volumes are already on the X, mitigating future price headwinds, and that they were supply-constrained in Q1 due to robust demand, expecting similar placement levels in Q2 with a strong pipeline for the back half. They acknowledged volume discounts for large multi-unit orders but emphasized the primary focus on driving consumables growth. 3. Operating margin progression and Q2 headwinds: Analysts inquired about the Q2 operating margin being lower than expected and the progression throughout the year, given specific headwinds like a higher instrument mix, inflationary pressures (component costs, freight), and a full quarter of SomaLogic. Management (Ankur) explained that mitigating actions are underway, starting in Q2, with their effects expected to become visible from Q3 into Q4, leading to an anticipated ramp-up in operating margin in the second half of the year.	Total revenue was up 4.8% year-over-year (1.2% on an organic basis). Sequencing consumables revenue was $726 million, up 4% year-over-year, with Rest of World organic growth of 5%. Clinical sequencing consumable demand, excluding China, grew 20%. Research and applied sequencing consumables, excluding China, declined 12%. Sequencing instruments revenue was $118 million, up 9% year-over-year (10% on a Rest of World organic basis). Sequencing service and other revenue was $151 million, up 7% year-over-year (5% on a Rest of World organic basis). The Microarrays business was down 20% on a Rest of World organic basis.

Transcript TidbitsTable

2026-04-30

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
Clinical markets are driving growth, making up over 65% of sequencing consumables revenue, fueled by the expansion of sequencing-based diagnostics and more data-intensive applications. Customers are launching new assays with ongoing reimbursement progress, supporting broader adoption of sequencing in clinical decision-making. Demand for comprehensive genomic profiling and whole genome sequencing is growing, increasing sequencing intensity, with NovaSeq X playing a central role. TruPath, a new whole genome sequencing workflow, is gaining significant interest, especially in rare disease, by simplifying standard of care and consolidating multiple tests. Illumina is on track to launch its spatial transcriptomics offering later this year, which has shown high engagement from early access users for challenging sample types. The NovaSeq X roadmap includes new 14B and 35B flow cells, staggered runs, and Q70 performance improvements, offering more flexibility, throughput, and workflow efficiency. BioInsight and the Billion Cell Atlas program are accelerating discovery and supporting AI-driven models for drug discovery, with growing partner interest. Clinical NovaSeq X placements are largely incremental, rather than conversions, immediately driving top-line growth.	Illumina does not see a substantial change in the competitive environment and looks forward to competing when new offerings reach the market. The company acknowledges competitive pricing discussions around cost per genome (e.g., $150 price point) but is not ready to discuss 35B flow cell pricing yet, focusing on elasticity and volume growth. Illumina views 10x Genomics' spatial launch positively, believing it drives overall interest in spatial biology, and sees room for multiple players due to different technologies and customer segments.	The clinical market shows sustained strength, while research and academic markets remain cautious due to funding uncertainty. There is alignment in Washington D.C. regarding NIH funding commitment, which is expected to pick up during the year, though translation into actual spending on tools and consumables may take time. The industry is experiencing near-term inflationary pressures related to freight costs and electronic components. The NovaSeq X transition for research customers is largely complete (over 90% volume), meaning less price headwind when that market recovers.	Illumina is raising its 2026 revenue guidance to $4.52 billion to $4.62 billion, operating margin expectations to 23.4% to 23.6%, and non-GAAP diluted EPS to $5.15 to $5.30, reflecting Q1 outperformance and business strength. The company remains on track for its 2027 targets of high single-digit revenue growth, continued margin expansion, and double-digit to teens EPS growth. Clinical market momentum is expected to continue into the coming years, with NovaSeq X placements driving consumables revenue approximately six months after installation. NovaSeq X placements are expected to be similar to Q1 levels (80+ units) in Q2, with a robust pipeline for the back half of the year, leading to full-year placements "reasonably above" the initial range. Investments are being made to scale NovaSeq X supply through Q2 and Q3 due to strong demand. Mitigating actions for inflationary pressures are expected to become visible in Q3 and Q4, leading to margin improvement in the second half of the year. The majority of clinical volumes (80% to 85%) are expected to transition to NovaSeq X by the end of 2026. Improvement in the research market due to easing funding uncertainties is considered an upside to the current guidance.	Diagnostics	Artificial Intelligence (AI) is mentioned in the context of BioInsight and the Billion Cell Atlas for accelerating discovery and supporting AI-driven models for drug discovery. Inflationary Pressures are noted as impacting freight costs and electronic components, requiring mitigating actions. Government Funding Dynamics, specifically NIH funding, are discussed regarding their impact on research spending.	We are off to a great start in 2026 with Q1 revenue, margin and EPS all coming in above our guidance range. Over 80 NovaSeq X placements in the quarter, approximately 20 more than Q1 '25, with year-over-year placements growth in both clinical and nonclinical markets. Clinical made up more than 65% of our sequencing consumables revenue in the quarter, driven by both the expansion of sequencing-based diagnostics and the increased use of more data-intensive applications. We see a long runway for continued growth in our clinical business. We are raising our 2026 guidance to reflect the Q1 outperformance. We also remain on track toward our 2027 targets and the investments we are making in R&D and product innovation position us to deliver high single-digit revenue growth, continued margin expansion and double-digit to teens EPS growth for years to come. In fact, during Q1, we were supply constrained on the number of NovaSeq X units that were placed as the demand continues to remain very robust. I think our placements of instruments shows that there's no freezing of any market that we are participating in at this point. We are around above $1.3 million of pull-through on the Xs. And we think that, that will continue to be at that level, if not above. We don't -- we're not seeing any signs of potential deceleration per se in that market. There's good momentum there.	In research and academic markets, demand remains cautious as customers navigate funding uncertainty. Sequencing consumables in research and applied declined 12% ex China, reflecting continued uncertainty in the funding environment during the quarter. Microarrays business was down 20% on a Rest of World organic basis, largely due to specific large customers in direct-to-consumer segment. Our guide assumes operating margins of approximately 22%, reflecting higher mix of instruments revenue and related investments, near-term inflationary pressures related to freight costs and higher cost of electronic components and a full quarter of SomaLogic as well. One thing is to have released grants, but the other thing is to have it all translated into spending the money on actually tools and consumables. And there are definitely some cautiousness with our customers before they've truly understand how those grants -- who are getting the grants and how many grants you're getting, there will be some cautiousness in that space for a little while.	Non-GAAP operating expenses were up 3% year-over-year, largely reflecting the addition of the SomaLogic team, indicating workforce expansion through acquisition.